BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FG-4592: Phase IIb started

Last October, FibroGen began an open-label Phase IIb trial to evaluate FG-4592 for 16 or 24 weeks in up to 144 CKD patients not on dialysis. Astellas' decision to advance...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >